Stéphane Jamain

List of Publications by Year
in descending order

125 papers	18,844 citations	36271 51 h-index	15249 126 g-index
152 all docs	152 docs citations	152 times ranked	21138 citing authors

#	Article	IF	Citations
1	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	9.4	2,067
2	Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nature Genetics, 2003, 34, 27-29.	9.4	1,612
3	Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature Genetics, 2011, 43, 977-983.	9.4	1,283
4	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	9.4	1,191
5	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	6.0	1,085
6	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	13.5	935
7	Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience, 2015, 18, 199-209.	7.1	701
8	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
9	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell, 2018, 173, 1705-1715.e16.	13.5	623
10	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry,the, 2019, 6, 427-436.	3.7	528
11	Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1710-1715.	3.3	489
12	Neuroligin 2 is exclusively localized to inhibitory synapses. European Journal of Cell Biology, 2004, 83, 449-456.	1.6	460
13	Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. American Journal of Psychiatry, 2017, 174, 850-858.	4.0	410
14	Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Molecular Psychiatry, 2014, 19, 1017-1024.	4.1	333
15	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	6.3	306
16	Linkage and association of the glutamate receptor 6 gene with autism. Molecular Psychiatry, 2002, 7, 302-310.	4.1	279
17	Genome-wide Association Study Identifies Genetic Variation in Neurocan as a Susceptibility Factor for Bipolar Disorder. American Journal of Human Genetics, 2011, 88, 372-381.	2.6	257
18	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. JAMA Psychiatry, 2018, 75, 36.	6.0	235

#	ARTICLE	IF	CITATIONS
19	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	2.3	229
20	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. American Journal of Human Genetics, 2015, 96, 283-294.	2.6	225
21	Identification of Pathways for Bipolar Disorder. JAMA Psychiatry, 2014, 71, 657.	6.0	204
22	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	1.3	193
23	GWAS of Suicide Attempt in Psychiatric Disorders and Association With Major Depression Polygenic Risk Scores. American Journal of Psychiatry, 2019, 176, 651-660.	4.0	186
24	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	1.4	182
25	Genome-wide association study meta-analysis of European and Asian-ancestry samples identifies three novel loci associated with bipolar disorder. Molecular Psychiatry, 2013, 18, 195-205.	4.1	180
26	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	1.1	156
27	Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Translational Psychiatry, 2017, 7, e1155-e1155.	2.4	150
28	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	3.7	141
29	The Genetics of the Mood Disorder Spectrum: Genome-wide Association Analyses of More Than 185,000 Cases and 439,000 Controls. Biological Psychiatry, 2020, 88, 169-184.	0.7	137
30	Improving genetic prediction by leveraging genetic correlations among human diseases and traits. Nature Communications, 2018, 9, 989.	5.8	136
31	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	0.7	114
32	Clinical Expression of Bipolar Disorder Type I as a Function of Age and Polarity at Onset. Journal of Clinical Psychiatry, 2012, 73, e561-e566.	1.1	113
33	Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder. Translational Psychiatry, 2012, 2, e201-e201.	2.4	107
34	Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. Journal of Affective Disorders, 2013, 148, 444-448.	2.0	102
35	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	6.0	102
36	Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis. Biological Psychiatry, 2017, 82, 634-641.	0.7	99

#	Article	IF	Citations
37	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. Schizophrenia Bulletin, 2015, 41, 559-573.	2.3	93
38	Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Human Molecular Genetics, 2012, 21, 4030-4037.	1.4	90
39	Common variant at 16p11.2 conferring risk of psychosis. Molecular Psychiatry, 2014, 19, 108-114.	4.1	85
40	Disruption of melatonin synthesis is associated with impaired 14-3-3 and miR-451 levels in patients with autism spectrum disorders. Scientific Reports, 2017, 7, 2096.	1.6	83
41	Exome Sequencing in 53 Sporadic Cases of Schizophrenia Identifies 18 Putative Candidate Genes. PLoS ONE, 2014, 9, e112745.	1.1	79
42	Reconsideration of bipolar disorder as a developmental disorder: Importance of the time of onset. Journal of Physiology (Paris), 2013, 107, 278-285.	2.1	77
43	A Conserved BDNF, Glutamate- and GABA-Enriched Gene Module Related to Human Depression Identified by Coexpression Meta-Analysis and DNA Variant Genome-Wide Association Studies. PLoS ONE, 2014, 9, e90980.	1.1	75
44	Association between circadian genes, bipolar disorders and chronotypes. Chronobiology International, 2014, 31, 807-814.	0.9	71
45	A SNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain. Molecular Psychiatry, 2010, 15, 748-755.	4.1	70
46	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychological Medicine, 2019, 49, 1378-1391.	2.7	69
47	Allelic differences between Europeans and Chinese for CREB1 SNPs and their implications in gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. Molecular Psychiatry, 2014, 19, 452-461.	4.1	61
48	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	0.7	61
49	Age at onset in bipolar I affective disorder in the USA and Europe. World Journal of Biological Psychiatry, 2014, 15, 369-376.	1.3	59
50	The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. Molecular Psychiatry, 2015, 20, 1448-1459.	4.1	59
51	Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. NeuroReport, 2004, 15, 1987-1991.	0.6	56
52	Genetic association study of circadian genes with seasonal pattern in bipolar disorders. Scientific Reports, 2015, 5, 10232.	1.6	56
53	Polymorphism of Toll-like receptor 4 gene in bipolar disorder. Journal of Affective Disorders, 2014, 152-154, 395-402.	2.0	53
54	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational Psychiatry, 2019, 9, 20.	2.4	52

#	ARTICLE	IF	CITATIONS
55	Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. Journal of Affective Disorders, 2015, 179, 161-166.	2.0	49
56	Y chromosome haplogroups in autistic subjects. Molecular Psychiatry, 2002, 7, 217-219.	4.1	44
57	Association of *AKT1* gene variants and protein expression in both schizophrenia and bipolar disorder. Genes, Brain and Behavior, 2010, 9, 503-511.	1.1	44
58	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	4.1	44
59	The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 645-657.	1.6	41
60	Effects of Cumulative Herpesviridae and Toxoplasma gondii Infections on Cognitive Function in Healthy, Bipolar, and Schizophrenia Subjects. Journal of Clinical Psychiatry, 2017, 78, e18-e27.	1.1	41
61	A mechanistic basis for amplification differences between samples and between genome regions. BMC Genomics, 2012, 13, 455.	1.2	40
62	Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes. Schizophrenia Research, 2012, 135, 8-14.	1.1	37
63	An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study. Genes, Brain and Behavior, 2014, 13, 299-304.	1.1	37
64	Circadian genes and lithium response in bipolar disorders: associations with PPARGC1A (PGC-1*α*) and RORA. Genes, Brain and Behavior, 2016, 15, 660-668.	1.1	37
65	A correction for sample overlap in genome-wide association studies in a polygenic pleiotropy-informed framework. BMC Genomics, 2018, 19, 494.	1.2	37
66	Variant *GADL1* and Response to Lithium in Bipolar I Disorder. New England Journal of Medicine, 2014, 370, 1855-1860.	13.9	36
67	Transduction of the Human Gene FAM8A1 by Endogenous Retrovirus During Primate Evolution. Genomics, 2001, 78, 38-45.	1.3	35
68	Common and Rare Variant Analysis in Early-Onset Bipolar Disorder Vulnerability. PLoS ONE, 2014, 9, e104326.	1.1	34
69	Bipolar multiplex families have an increased burden of common risk variants for psychiatric disorders. Molecular Psychiatry, 2021, 26, 1286-1298.	4.1	33
70	Mutation screening of NOS1AP gene in a large sample of psychiatric patients and controls. BMC Medical Genetics, 2010, 11, 108.	2.1	31
71	The HLA-G low expressor genotype is associated with protection against bipolar disorder. Human Immunology, 2013, 74, 593-597.	1.2	30
72	A Multilevel Functional Study of a *SNAP25* At-Risk Variant for Bipolar Disorder and Schizophrenia. Journal of Neuroscience, 2017, 37, 10389-10397.	1.7	29

#	Article	IF	Citations
73	Childhood maltreatment and polygenic risk in bipolar disorders. Bipolar Disorders, 2020, 22, 174-181.	1.1	29
74	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	1.3	28
75	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. World Journal of Biological Psychiatry, 2020, 21, 775-783.	1.3	27
76	Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with Intellectual Disability. BMC Medical Genetics, 2011, 12, 17.	2.1	25
77	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	2.4	25
78	An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disorders, 2020, 22, 255-265.	1.1	24
79	Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 491-494.	1.1	23
80	A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia. Translational Psychiatry, 2015, 5, e608-e608.	2.4	22
81	Convergent Lines of Evidence Support LRP8 as a Susceptibility Gene for Psychosis. Molecular Neurobiology, 2016, 53, 6608-6619.	1.9	20
82	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.1	20
83	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
84	Identification of the Human KIF13A Gene Homologous to Drosophila kinesin-73 and Candidate for Schizophrenia. Genomics, 2001, 74, 36-44.	1.3	17
85	European Network of Bipolar Research Expert Centre (ENBREC): a network to foster research and promote innovative care. International Journal of Bipolar Disorders, 2013, 1, 2.	0.8	17
86	Interaction between SLC6A4 promoter variants and childhood trauma on the age at onset of bipolar disorders. Scientific Reports, 2015, 5, 16301.	1.6	17
87	Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. Communications Biology, 2018, 1, 163.	2.0	17
88	Immunoglobulin sub-class distribution in bipolar disorder and schizophrenia: potential relationship with latent Toxoplasma Gondii infection. BMC Psychiatry, 2018, 18, 239.	1.1	17
89	European collaborative study of earlyâ€onset bipolar disorder: Evidence for genetic heterogeneity on 2q14 according to age at onset. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1425-1433.	1.1	16
90	Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth. Journal of Psychopharmacology, 2020, 34, 370-379.	2.0	15

#	Article	IF	Citations
91	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. Schizophrenia Bulletin, 2020, 46, 517-529.	2.3	14
92	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. Biological Psychiatry, 2021, 90, 9-15.	0.7	14
93	Genetic heterogeneity according to age at onset in bipolar disorder: A combined positional cloning and candidate gene approach. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 653-659.	1.1	13
94	Differential expression of VGLUT3 in laboratory mouse strains: Impact on drug‐induced hyperlocomotion and anxiety‐related behaviors. Genes, Brain and Behavior, 2019, 18, e12528.	1.1	13
95	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11, 423.	2.4	12
96	Impact of a <i>cis</i>-associated gene expression SNP on chromosome 20q11.22 on bipolar disorder susceptibility, hippocampal structure and cognitive performance. British Journal of Psychiatry, 2016, 208, 128-137.	1.7	11
97	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	1.7	11
98	Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE). Psychological Medicine, 2019, 49, 2600-2607.	2.7	10
99	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	1.6	10
100	Identification of a Bipolar Disorder Vulnerable Gene CHDH at 3p21.1. Molecular Neurobiology, 2017, 54, 5166-5176.	1.9	9
101	A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). Journal of Psychopharmacology, 2020, 34, 524-531.	2.0	9
102	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. Psychological Medicine, 2023, 53, 3396-3405.	2.7	9
103	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case–Control Study. Schizophrenia Bulletin, 2022, 48, 1104-1114.	2.3	9
104	Using admixture analysis to examine birth‐cohort effects on age at onset of bipolar disorder. Acta Psychiatrica Scandinavica, 2016, 133, 205-213.	2.2	8
105	Animal Models of Autism. Contemporary Clinical Neuroscience, 2006, , 151-174.	0.3	7
106	Genetic and molecular exploration of UHMK1 in schizophrenic patients. Psychiatric Genetics, 2011, 21, 315-318.	0.6	7
107	Genome-wide Association Study Identifies Genetic Variation in Neurocan as a Susceptibility Factor for Bipolar Disorder. American Journal of Human Genetics, 2011, 88, 396.	2.6	6
108	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – A possible therapeutic mechanism. World Journal of Biological Psychiatry, 2019, 20, 766-777.	1.3	5

#	ARTICLE	IF	CITATIONS
109	Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses. Neuropsychopharmacology, 2020, 45, 1637-1644.	2.8	5
110	Contribution of common and rare damaging variants in familial forms of bipolar disorder and phenotypic outcome. Translational Psychiatry, 2020, 10, 124.	2.4	5
111	The Complement C4 Genetic Diversity in First Episode Psychosis of the OPTiMiSE Cohort. Schizophrenia Bulletin Open, 2021, 2, .	0.9	5
112	TLR4 gene polymorphism associated with lifetime cigarette smoking in bipolar disorder. Journal of Neuroimmunology, 2017, 305, 96-101.	1.1	3
113	Santé physique et troubles bipolaires. Annales Medico-Psychologiques, 2012, 170, 56-61.	0.2	2
114	Schizophrenia: Developmental Variability Interacts with Risk Factors to Cause the Disorder. BioEssays, 2020, 42, 2000038.	1.2	2
115	Antidepressantâ€like effect of low dose of scopolamine in the H/Rouen genetic mouse model of depression. Fundamental and Clinical Pharmacology, 2020, 35, 645-649.	1.0	2
116	No alteration of leukocyte telomere length in first episode psychosis. Psychiatry Research, 2021, 301, 113941.	1.7	2
117	31.4 GENETIC, IMMUNOLOGICAL AND BIOCHEMICAL MARKERS OF TREATMENT RESPONSE IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S51-S51.	2.3	1
118	CADPS functional mutations in patients with bipolar disorder increase the sensitivity to stress. Molecular Psychiatry, 2022, 27, 1145-1157.	4.1	1
119	Autism and autistics disorders. , 2006, , 249-263.		0
120	Poster #110 NO ASSOCIATION BETWEEN SNAP-25 GENE POLYMORPHISMS AND WEIGHT GAIN IN ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S225.	1.1	0
121	P.1.e.023 Functional mutations in CADPS identified in patients with early-onset bipolar disorder. European Neuropsychopharmacology, 2015, 25, S222-S223.	0.3	0
122	M22 COMMON AND RARE DAMAGING VARIANTS BOTH CONTRIBUTE TO FAMILIAL FORM OF BIPOLAR DISORDER AND EXPLAIN DIFFERENCE IN CLINICAL MANIFESTATIONS IN MULTIPLEX FAMILIES. European Neuropsychopharmacology, 2019, 29, S178.	0.3	0
123	F3. CHILDHOOD MALTREATMENT AND POLYGENIC RISK IN BIPOLAR DISORDERS. Schizophrenia Bulletin, 2019, 45, S255-S256.	2.3	0
124	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTiMiSE COHORT STUDY. Schizophrenia Bulletin, 2019, 45, S116-S117.	2.3	0
125	A MULTI-LEVEL FUNCTIONAL STUDY OF A SNAP25 AT-RISK VARIANT FOR BIPOLAR DISORDER AND SCHIZOPHRENIA. European Neuropsychopharmacology, 2019, 29, S1009-S1010.	0.3	0